Free Trial

RTW Biotech Opportunities (RTW) Competitors

RTW Biotech Opportunities logo
GBX 1.48 0.00 (0.00%)
(As of 11/22/2024 ET)

RTW vs. DVNO, LFI, TPVE, PMGR, YOLO, FFWD, JTWO, VEN2, TEK, and FIPP

Should you be buying RTW Biotech Opportunities stock or one of its competitors? The main competitors of RTW Biotech Opportunities include Develop North (DVNO), London Finance & Investment Group (LFI), Triple Point Income VCT Plc E (TPVE), Premier Miton Glb Renewables Trust (PMGR), Yolo Leisure and Technology (YOLO), Fastforward Innovations (FFWD), J2 Acquisition (JTWO), Ventus 2 VCT (VEN2), Tekcapital (TEK), and Frontier IP Group (FIPP). These companies are all part of the "asset management" industry.

RTW Biotech Opportunities vs.

Develop North (LON:DVNO) and RTW Biotech Opportunities (LON:RTW) are both small-cap financial services companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, community ranking, institutional ownership and valuation.

RTW Biotech Opportunities has a net margin of 1,994.76% compared to Develop North's net margin of 31.11%. RTW Biotech Opportunities' return on equity of 21.42% beat Develop North's return on equity.

Company Net Margins Return on Equity Return on Assets
Develop North31.11% 1.22% 1.11%
RTW Biotech Opportunities 1,994.76%21.42%-0.47%

Develop North has a beta of 0.16, meaning that its stock price is 84% less volatile than the S&P 500. Comparatively, RTW Biotech Opportunities has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500.

3.9% of RTW Biotech Opportunities shares are held by institutional investors. 19.4% of Develop North shares are held by insiders. Comparatively, 16.2% of RTW Biotech Opportunities shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

RTW Biotech Opportunities received 1 more outperform votes than Develop North when rated by MarketBeat users.

CompanyUnderperformOutperform
Develop NorthN/AN/A
RTW Biotech OpportunitiesOutperform Votes
1
100.00%
Underperform Votes
No Votes

RTW Biotech Opportunities has higher revenue and earnings than Develop North. RTW Biotech Opportunities is trading at a lower price-to-earnings ratio than Develop North, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Develop North£1.13M15.47N/A£0.017,000.00
RTW Biotech Opportunities£4.17M1.19£83.19M£0.364.11

In the previous week, Develop North had 1 more articles in the media than RTW Biotech Opportunities. MarketBeat recorded 1 mentions for Develop North and 0 mentions for RTW Biotech Opportunities. Develop North's average media sentiment score of 1.00 beat RTW Biotech Opportunities' score of 0.00 indicating that Develop North is being referred to more favorably in the media.

Company Overall Sentiment
Develop North Positive
RTW Biotech Opportunities Neutral

Summary

RTW Biotech Opportunities beats Develop North on 7 of the 13 factors compared between the two stocks.

Get RTW Biotech Opportunities News Delivered to You Automatically

Sign up to receive the latest news and ratings for RTW and its competitors with MarketBeat's FREE daily newsletter.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RTW vs. The Competition

MetricRTW Biotech OpportunitiesAsset Management IndustryFinancial SectorLON Exchange
Market Cap£4.97M£943.12M£3.77B£1.81B
Dividend YieldN/A5.67%4.37%6.70%
P/E Ratio4.11760.82400.961,789.93
Price / Sales1.193,941.872,502.62286,444.85
Price / Cash0.3248.9643.3623.88
Price / Book0.011.641.462.93
Net Income£83.19M£59.78M£455.76M£183.97M
7 Day Performance-4.52%0.65%1.17%-0.04%
1 Month Performance-4.21%0.63%2.00%-0.45%
1 Year Performance29.03%11.17%15.68%25.31%

RTW Biotech Opportunities Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RTW
RTW Biotech Opportunities
N/AGBX 1.48
flat
N/A+29.8%£4.97M£4.17M4.114,971
DVNO
Develop North
N/AGBX 78
flat
N/A-20.5%£19.48M£1.13M7,800.00N/ADividend Announcement
Positive News
Gap Down
LFI
London Finance & Investment Group
N/AGBX 58
-4.9%
N/A+81.3%£18.10M£1.69M414.294
TPVE
Triple Point Income VCT Plc E
N/AN/AN/AN/A£18.09M£4.35M781.25N/A
PMGR
Premier Miton Glb Renewables Trust
N/AGBX 96.50
flat
N/AN/A£17.60M£7.16M-402.08N/ANews Coverage
YOLO
Yolo Leisure and Technology
N/AGBX 18.75
+4.5%
N/A+0.0%£17.57M£14,000.00-12.502
FFWD
Fastforward Innovations
N/AGBX 8.25
flat
N/AN/A£17.55M£-4,193,000.00-2.50N/A
JTWO
J2 Acquisition
N/AGBX 9.40
flat
N/AN/A£15.97M£3.88B-1.97N/A
VEN2
Ventus 2 VCT
N/AGBX 42
-53.6%
N/AN/A£15.82M£9.47M1.98N/AGap Down
TEK
Tekcapital
N/AGBX 7.90
-3.1%
N/A+8.7%£15.66M£16.74M154.166
FIPP
Frontier IP Group
N/AGBX 27.37
-2.3%
N/A-29.3%£15.37M£-1,380,000.00-684.1321

Related Companies and Tools


This page (LON:RTW) was last updated on 11/24/2024 by MarketBeat.com Staff
From Our Partners